Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome

May 15, 2025 Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
News

Kaerus Bioscience secures FDA approval for rare genetic disorder treatment

May 15, 2025 Research and Development FDA, Fragile X syndrome, Kaerus Bioscience, Orphan Drug Designation (ODD), Rare Diseases, Rare Pediatric Drug Designations (RPDD), genetic syndromes

Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug …
News
handshake_2

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement

May 14, 2025 Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement

Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …
News

Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing

May 14, 2025 Manufacturing and Production, Research and Development CGT production, Cell and Gene Therapy (CGT), Contraception, Pharmacy, Tozaro, advisory board

Tozaro, a UK-based biopharma focused on cell and gene therapy (CGT), has announced the formation of a Technical Advisory Board …
News

Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president

May 14, 2025 Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology

Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Appointment

Donato Spota appointed as chief financial officer at Eleva

May 14, 2025 Research and Development Eleva, Pharmacy, appointment, biopharma, chief financial officer (CFO)

German biopharma company, Eleva, has appointed Donato Spota as its new chief financial officer (CFO) and managing director to support …
Appointment
mental-health-3332122_960_720

Newron’s programme for treatment-resistant schizophrenia therapy approved

May 13, 2025 Research and Development Newron, Psychiatry, clinical trials, psychiatry, schizophrenia

Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
News

Thermosome secures FDA Orphan Drug Designation for soft tissue sarcoma therapy

May 12, 2025 Research and Development European Medicines Agency (EMA), FDA, Oncology, Thermosome

Thermosome has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead candidate, THE001, …
News
researchers_credit_neusentis_pfizer

Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025

May 12, 2025 Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide

Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
News

Moderna expands use of AI-ready R&D platform

May 12, 2025 Business Services, Research and Development, Technical Consultancy AI, Benchling, Corporate, Moderna, R&D, digital transformation

Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader research organisation. Previously used by …
News
bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025 Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
News

Mind the gap: men’s health and the need for progress

May 12, 2025 Advocacy Development, Medical Communications, Medical Education, Research and Development Androlabs, Men's Health Strategy, Men's mental health, Movember Foundation, Pharmacy, Psychiatry, mental health

From prostate cancer to hormonal health, many areas of men’s health require more attention. As male life expectancy and healthy …
Feature
Thought Leadership

Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases

May 9, 2025 Research and Development Galimedix Therapeutics, Neurology, Opthalmology, R&D, clinical trial, neurodegenerative conditions

Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study …
News

AAX Biotech announces collaboration for cardiovascular antibody therapy

May 8, 2025 Research and Development AAX Biotech, Cardiology, antibody therapies, collaboration, research and development

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of antibody-based therapies targeting cardiovascular disease. …
News

Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds

May 8, 2025 Research and Development AI, Corporate, Devices, EU Data Act, HCPs, Johnson & Johnson, Pharmacy, digital technology, survey

A global survey by Johnson & Johnson MedTech has revealed that a majority of Europeans are willing to share their …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025